Skip to main content
. 2014 Oct 15;24(6):791–801. doi: 10.1089/scd.2014.0174

FIG. 1.

FIG. 1.

AdIGF-I-MSCs treatment further ameliorates liver fibrosis. (A) Dosage of insulin growth factor like-I (IGF-I) in culture's supernatant of AdIGF-I-MSCs and AdGFP-MSCs at day 2, 4, 6, 8, and 10 postinfection. **P<0.01; ****P<0.0001; * versus AdGFP-MSCs. (B) Experimental in vivo model (see Materials and Methods section). (C) Representative microphotographies of Masson's trichrome and sirius red-stained and alpha-smooth muscle actin (α-SMA) immunostained liver sections (scale bars: 100 μm). Quantification of collagen deposits based on sirius red-stained sections and of α-SMA-positive cells, by morphometric analysis [thioacetamide (TAA) model]. (D) Representative microphotographies of sirius red-stained liver sections from mice subjected to bile duct ligation and treated with mesenchymal stromal cells (MSCs) (BDL model). Quantification of collagen deposits based on sirius red stainings. *σP<0.05; **σσP<0.01; ***σσσP<0.001. * versus saline; σ versus AdGFP-MSCs.